2024
Single-molecule microfluidic assay for prostate-specific antigen based on magnetic beads and upconversion nanoparticles
SKLENÁROVÁ, Dorota; Antonín HLAVÁČEK; Jana KŘIVÁNKOVÁ; Julian BRANDMEIER; Julie WEISOVÁ et. al.Basic information
Original name
Single-molecule microfluidic assay for prostate-specific antigen based on magnetic beads and upconversion nanoparticles
Authors
SKLENÁROVÁ, Dorota (703 Slovakia, belonging to the institution); Antonín HLAVÁČEK (203 Czech Republic); Jana KŘIVÁNKOVÁ (203 Czech Republic); Julian BRANDMEIER (276 Germany, belonging to the institution); Julie WEISOVÁ; Michal ŘIHÁČEK (203 Czech Republic, belonging to the institution); Hans-Heiner GORRIS (276 Germany, belonging to the institution); Petr SKLÁDAL (203 Czech Republic, belonging to the institution) and Zdeněk FARKA (203 Czech Republic, guarantor, belonging to the institution)
Edition
Lab on a Chip, Cambridge, Royal Society of Chemistry, 2024, 1473-0197
Other information
Language
English
Type of outcome
Article in a journal
Field of Study
10406 Analytical chemistry
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
is not subject to a state or trade secret
References:
Impact factor
Impact factor: 6.100 in 2023
RIV identification code
RIV/00216224:14310/24:00139473
Organization unit
Faculty of Science
UT WoS
001258448900001
EID Scopus
2-s2.0-85197932979
Keywords in English
Photon-upconversion nanoparticle; Immunoassay; Microfluidics; Prostate-specific antigen
Tags
International impact, Reviewed
Changed: 4/4/2025 13:19, Mgr. Marie Novosadová Šípková, DiS.
Abstract
V originále
Early-stage diagnosis of prostatic carcinoma is essential for successful treatment and, thus, significant prognosis improvement. In laboratory practice, the standard non-invasive diagnostic approach is the immunochemical detection of the associated biomarker, prostate-specific antigen (PSA). Ultrasensitive detection of PSA is essential for both diagnostic and recurrence monitoring purposes. To achieve exceptional sensitivity, we have developed a microfluidic device with a flow-through cell for single-molecule analysis using photon-upconversion nanoparticles (UCNPs) as a detection label. For this purpose, magnetic microparticles (MBs) were first optimized for the capture and preconcentration of PSA and then used to implement a bead-based upconversion-linked immunoassay (ULISA) in the microfluidic device. The digital readout based on counting single nanoparticle-labeled PSA molecules on MBs enabled a detection limit of 1.04 pg mL−1 (36 fM) in 50% fetal bovine serum, which is an 11-fold improvement over the respective analog MB-based ULISA. The microfluidic technique conferred several other advantages, such as easy implementation and the potential for achieving high-throughput analysis. Finally, it was proven that the microfluidic setup is suitable for clinical sample analysis, showing a good correlation with a reference electrochemiluminescence assay (recovery rates between 97% and 105%).
Links
GA21-03156S, research and development project |
|